Allergan Posts Flat Q3 Profit, Lifts Low End Of Earnings Outlook
(RTTNews.com) – Multi-specialty health care company Allergan Inc. (AGN) on Tuesday reported a profit for the third quarter that was flat with last year despite higher sales of ...
Orthofix forks over $32M to settle kickback case
By Damian Garde
Orthofix International ($OFIX) has settled the kickback case against its Blackstone Medical subsidiary, paying $32 million to resolve charges that the company paid ...
CryoLife revenue jumped in Q3
The company’s sales gains came, in part, from M&A, but a growing surgical sealant business also helped
By Mark Hollmer
CryoLife ($CRY) celebrates a robust 2012 third quarter ...
Stryker CEO touts paradigm shift
Kevin Lobo says the devicemaker is looking at clinical and economic evidence in R&D
By Damian Garde
Kevin Lobo took the tob job at Stryker ($SYK) last month, and he said ...
Updated: Medtronic looks to unseat Edwards with heart valve
By Damian Garde
Medtronic ($MDT) is inching toward European approval for its Engager heart valve, releasing data demonstrating the device to be safe and effective.
Edwards Lifesciences ...
Allergan mulls sale of its anti-obesity device business
The news comes following setbacks in gaining expanded approval for Allergan’s Lap-Band device
By Mark Hollmer
Allergan ($AGN) may unload its anti-obesity device business, the ...
Cigarette maker Philip Morris rolls vaccine interests into China
By Ryan McBride
Craving growth in the huge market for tobacco products in China, Philip Morris International ($PM) has invested in rights to flu vaccines made from a species of tobacco ...
Neuraltus Pharma eyes PhIII after missing endpoints in trial for ALS drug
By Ryan McBride
Despite falling short of goals in a Phase II trial, Neuraltus Pharmaceuticals saw enough evidence of efficacy in Lou Gehrig’s disease patients on its experimental ...
Theratechnologies once again tries to slash its way to breakeven point
By John Carroll
Ten months ago, Montreal-based Theratechnologies ($THER) cut its staff, shelved a mid-stage development program and slashed costs, vowing to get on track to profitability ...
Alzheimer’s investigators see fresh sign of solanezumab success in Eli Lilly study
By John Carroll
Researchers took the center stage at an Alzheimer’s conference in Monaco to offer late-stage biomarker evidence to support Eli Lilly’s optimism about ...
Aveo slashes workforce, circles wagons around troubled kidney cancer drug
By John Carroll
Struggling to overcome growing doubts about the future of its lead cancer drug, Cambridge, MA-based Aveo ($AVEO) this morning announced that it will shrink its workforce ...
Boehringer Ingelheim bets bigger on respiratory drugs
German drugmaker expanding inhaler plant for second time
By Eric Palmer
With respiratory drugs helping to fuel its earnings and new ones in the pipeline, Boehringer Ingelheim is ...